Abnormal dermatoglyphic pattern
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormal hair quantity
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormal platelet function
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of coagulation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of dental color
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of finger
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of pulmonary valve
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of the spleen
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of toe
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Abnormality of vision
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Acquired genu recurvatum
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Acquired Kyphoscoliosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Acquired porencephaly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Acral Lentiginous Malignant Melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Novel studies investigating the biologic characteristics of acral MM reported variable results: the overall mutational rates ranged respectively between 8.5% and 23% for KIT, between 3.6% and 33.3% for BRAF and between 3% and 47% for NRAS in ALMs.
|
29512974 |
2019 |
Acral Lentiginous Malignant Melanoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were found in 9.3% of the cases, BRAF in 10.3%, NRAS in 7.5%, KIT in 20.7%, and PDGFRA in 14.8% of ALM.
|
26709572 |
2016 |
Acromegaly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Despite the relation of BRAF V600E and NRAS codon 61 mutations with aggresive histopathologic features, their impact on tumor prognosis remains to be defined in acromegaly in further studies.
|
26575115 |
2016 |
Acute Erythroblastic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These three MDS patients with p53 gene mutations and an MDS-derived erythroleukemia cell line that we had previously reported to carry a p53 gene mutation showed no N-ras gene mutations, suggesting heterogeneity in the oncogenic mechanism of MDS.
|
8499637 |
1993 |
Acute Erythroblastic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
We show here, for the first time, that both N-RAS and H-RAS can impair erythroid differentiation of erythroleukaemia cells induced with hexamethylene bisacetamide.
|
9301684 |
1997 |
Acute leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
A trend was found between the overexpression of the N-ras gene and the acute leukemias: all 10 acute leukemias exhibited overexpression of the N-ras gene, while only two of the CML cases, both in blastic crisis, showed elevated levels of the N-ras gene.
|
8948029 |
1996 |
Acute leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
|
25833960 |
2015 |
Acute leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Our observations indicate that in vivo selection assays detect transforming genes including ras oncogenes at high frequency, and that activated N-ras genes are frequently detected in human acute leukemias.
|
3632661 |
1987 |
Acute leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.
|
26222068 |
2015 |
Acute leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.
|
16404744 |
2006 |
Acute leukemia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The authors analyzed MIN in de novo acute leukemia and its association with expression of the human MSH3 (hMSH3) gene and point mutations of the N-ras gene.
|
9690540 |
1998 |